Phaseline

Companies › Legend Biotech USA

Legend Biotech USA: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology, Gastroenterology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LB1908
anti-CLDN18.2 CAR-T cell therapy
CLDN18Phase 1Gastric CancerDec 2027
LB2102
DLL3-directed autologous chimeric antigen receptor T-cell (CAR-T) therapy
–Phase 1Small Cell Lung Cancer Extensive StageDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05680922LB2102Phase 1Small Cell Lung Cancer Extensive StageOncologyDec 2027
NCT05539430LB1908Phase 1Gastric CancerGastroenterologyDec 2027

Targets

CLDN18 (1)

Companies with the same targets

Astellas AstraZeneca RemeGen Shanghai Institute Of Biological Products Beijing Biotech Sichuan Kelun-Biotech Biopharmaceutical Biokin (Shanghai) Biopharmaceutical Transcenta Therapeutics (Hangzhou) Shanghai Hengrui Pharmaceutical Innovent Biologics (Suzhou)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.